Healthy Volunteers Clinical Trial
Official title:
Impact of Ketone Bodies on Myocardial Glucose and Fatty Acid Metabolism in Healthy Volunteers: A Positron Emission Tomography Study
Starvation and metabolic stress increase circulating ketone bodies, potentially providing
the heart with an alternative oxidative fuel. Hyperketonemia reduces myocardial fatty acid
consumption. It is unclear whether this is due to inhibited peripheral lipolysis or
diminished uptake per se.
Aim: To test whether infusion of 3-hydroxybutyrate (BHB) inhibits myocardial glucose and
fatty acid uptake.
Methods: Randomized, single blinded, cross-over interventional study in 8 healthy
volunteers. Myocardial glucose and fatty acid metabolism studied by 11C-palmitate and
18F-FDG PET/CT. Experimental elevation of circulating ketone bodies by infusion of
β-hydroxy-β-methylbutyrate.
Background:
Ketone bodies are produced by the liver in conditions of increased fatty acid oxidation,
serving as important fuel sources during fasting and starvation. They are metabolized to
acetyl-CoA which enters the tricarboxylic acid cycle, enabling ATP production independently
of glycolysis and resulting in lower oxygen consumption per mole of produced ATP compared to
glucose [ref]. Their primary physiological function appears to be as an alternative
protein-sparing source of energy for extrahepatic tissues in times of reduced carbohydrate
availability, preventing muscle wasting. The principal ketone bodies in humans are
beta-hydroxybutyrate (BHB) and acetoacetate. Increased ketogenesis is a feature common to
fasting, starvation and diabetes mellitus. Ketones have been shown to have a number of
neuroprotective effects including anticonvulsant activity, improving cognitive function in
Alzheimer's disease and decreasing the effects of acute brain injury and ischemic damage
[ref], as well as antitumoral effect in gliomas. This has led to the suggestion that ketones
could be used therapeutically for a number of diseases though currently the only recognized
therapeutic use of ketones is in the form of ketogenic diets for the treatment of epilepsy.
There are limited in vivo studies on the effect of ketones on the heart. It is known that
fatty acids are the preferred myocardial fuel substrate and that this shifts to increased
use of glucose, and to a lesser extent ketones, in times of acutely increased demand.
Interestingly, acute ketone infusion in pigs appears to inhibit myocardial fatty acid
oxidation. In vitro studies suggest ketones decrease myocardial glucose uptake and affect
myocardial contractility, with either increased or decreased contractility when ketones are
the only energy source. This has not been further investigated in vivo. It is therefore
unclear to what extent ketones can contribute to myocardial metabolism in conditions of
hyperketonemia, and how this affects contractility.
The present project thus proposes to address the issues outlined above, by measuring human
cerebral and cardiac uptake of energy substrates, together with functional parameters, using
PET imaging and appropriate radiotracers, under experimental hyperketonemia.
Hypotheses:
1. An acute increase in blood ketone concentration without previous ketoadaptation will
decrease cardiac palmitate and glucose uptake in healthy humans.
Materials and methods
Effect of acute ketone infusion on cardiac perfusion and 18F-FDG and 11C-palmitate uptake in
healthy subjects:
Study population: 10 healthy volunteers. All study subjects will be instructed to follow a
standardised diet for 1 week before the study. On the study day, they will undergo a
baseline dynamic cardiac PET scan with 15O-water followed by 11C-palmitate and 18F-FDG
tracers, together with baseline blood samples, muscle biopsy and subcutaneous fat biopsy to
assess peripheral metabolic status. An intravenous infusion of sodium betahydroxybutyrate
will then be initiated at a concentration and rate sufficient to achieve 1-2 mM ketonemia
after 30 minutes (assessed by blood sample). A second dynamic PET scan identical to the
first will then be performed under continuous ketone infusion at a constant rate. Finally, a
second set of blood samples, muscle and subcutaneous fat biopsies will be taken after the
scan before stopping the ketone infusion.
Perspectives:
The results of this research are expected to provide insights into how human heart
metabolism respond to increased ketone bodies, and whether there are significant functional
improvements. It should contribute to further understanding the possible therapeutic
benefits of both exogenous ketone administration and of fasting in relation to cardiac
function, with implications for the treatment of various diseases such as diabetes and heart
failure. Knowledge of ketones' effects on the kinetics of various radionuclide tracers also
has importance for the appropriate clinical use of diagnostic PET scans in patients with
elevated blood ketone levels. In addition, the implementation and validation of a ketone PET
tracer will allow further future non-invasive studies that directly measure ketone
metabolism in various tissues and disease states.
;
Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
| Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
| Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
| Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
| Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
| Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
| Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
| Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
| Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
| Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
| Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
| Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
| Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
| Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
| Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
| Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
| Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
| Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |